Live Breaking News & Updates on Navex

Stay informed with the latest breaking news from Navex on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Navex and stay connected to the pulse of your community

Bragar Eagel & Squire, P.C. Reminds Investors That Class

NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...

California , United-states , New-york , South-carolina , Brandon-walker , Williamj-sandborn , Marion-passmore , Bragar-eagel-squire , Ventyx-biosciences-inc , Anavex-life-sciences-corp , Nasdaq , Exchange-commission

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages

The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses to Contact the Firm...

Brian-schall , Los-angeles , Exchange-commission , Schall-law-firm , Securities-exchange , Anavex-life-sciences-corp , Anavex-life-sciences , Securities-exchange-act , Park-east , Attorney-advertising , Schall-law , Vxl

Bragar Eagel & Squire, P.C. Reminds Investors That Class

NEW YORK, March 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...

California , United-states , South-carolina , Texas , King-mountain , New-york , Bragar-eagel-squire , Brandon-walker , Marion-passmore , Anavex-life-sciences-corp , Mining-corp , Us-bitcoin-corp

SHAREHOLDER ALERT: Anavex Life Sciences Sued for Securities

BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) for securities law...

Boston , Massachusetts , United-states , Nasdaq , Anavex-life-sciences-corp , Block-leviton , Anavex-life-sciences , Block-amp-leviton-llp , Navex , Vxl , Ecurities-fraud

Anavex Life Sciences Investigated by Block & Leviton For

BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) for potential securities law...

Boston , Massachusetts , United-states , Block-leviton , Nasdaq , Anavex-life-sciences-corp , Anavex-life-sciences , Block-amp-leviton-llp , Navex , Vxl , Ett-syndrome

ANAVEX Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine)

NEW YORK, June 01, 2023 -- Anavex Life Sciences Corp. , a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and... | June 1, 2023

United-states , Andrewj-barwicki , Christopheru-missling , Globenewswire-inc , Research-business-development , Instagram , Nasdaq , Linkedin , Trademark-office , Anavex-life-sciences-corp , Michaelj-fox-foundation-for-parkinson-research

Anavex Life Sciences : Announces Issuance of New U.S. Patent ANAVEX®2-73 (blarcamesine)

Intellectual Property Portfolio for the Treatment of Hypertension

Anavex Life Sciences Corp. , a clinical-stage biopharmaceutical company developing... | May 1, 2023

United-states , Christopheru-missling , Andrewj-barwicki , Linkedin , Instagram , Twitter , Trademark-office , Michaelj-fox-foundation-for-parkinson-research , Facebook , Company-nasdaq , Research-business-development

Anavex Life Sciences : to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

Anavex Life Sciences Corp. , a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders... | April 25, 2023

New-york , United-states , Christopheru-missling , Michaelj-fox-foundation-for-parkinson-research , Linkedin , Facebook , Anavex-life-sciences-corp , Company-nasdaq , Research-business-development , Twitter , Nasdaq

ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson's Disease Dementia

Study successfully achieved both primary and secondary objectives ANAVEX®2-73 treatment resulted in improvements of all efficacy endpoints over 48 Weeks Anavex plans to proceed to... | March 30, 2023

Montreal , Quebec , Canada , United-states , Christopheru-missling , Andrewj-barwicki , Nasdaq , Parkinson-progression-markers-initiative-cohort , Company-nasdaq , Research-business-development , Twitter , Parkinson-progression-marker-initiative

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

Anavex Life Sciences Corp. announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 for the treatment of mild cognitive impairment due to... | December 2, 2022

San-francisco , California , United-states , Anavex-life-sciences-corp , Anavex-life-sciences , Clinical-trials , Odds-ratio , Clinical-dementia-rating-scale-sum , Anavex-life-sciences-corp-stock-exchange , Ews , Nformation